Mosaic receptor binding domain nanoparticles: towards fourth-generation vaccination

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants – clinical, public health, and vaccine implications. N. Engl. J. Med. 384(19), 1866–1868 (2021).
  MedlineGoogle Scholar
• 2. Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: an update. Curr. Res. Pharmacol. Drug Discov. 100086 (2022).
  MedlineGoogle Scholar
• 3. Rathnasinghe R, Jangra S, Ye C et al. Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera. Nat. Commun. 13(1), 1–14 (2022).
  MedlineGoogle Scholar
• 4. Chavda VP, Patel AB, Vaghasiya DD. SARS-CoV-2 variants and vulnerability at the global level. J. Med. Virol. 94, 2986–3005 (2022).
  Medline CASGoogle Scholar
• 5. Chavda VP, Apostolopoulos V. Global impact of delta plus variant and vaccination. Expert Rev. Vaccines 21(5), 597–600 (2022).
  Medline CASGoogle Scholar
• 6. Chavda VP, Pandya R, Apostolopoulos V. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Rev. Vaccines 20(12), 1549–1560 (2021).
  Medline CASGoogle Scholar
• 7. Chavda VP, Vuppu S, Mishra T et al. Recent review of COVID-19 management: diagnosis, treatment and vaccination. Pharmacol. Rep. 74, 1120–1148 (2022).
  MedlineGoogle Scholar
• 8. Andrews N, Tessier E, Stowe J et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N. Engl. J. Med. 386(4), 340–350 (2022).
  Medline CASGoogle Scholar
• 9. Chiappelli F. 2019-nCoV – towards a 4th generation vaccine. Bioinformation 16(2), 139–144 (2020).
  MedlineGoogle Scholar
• 10. Cohen AA, Gnanapragasam PNP, Lee YE et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 371(6530), 735–741 (2021). •• Describes the potential of mosaic nanoparticles against SARS-CoV-2.
  Medline CASGoogle Scholar
• 11. Joyce MG, Chen W-H, Sankhala RS et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 37(12), 110143 (2021).
  Medline CASGoogle Scholar
• 12. Fan C, Cohen AA, Park M et al. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes. Immunity S107476132200560X (2022).
  Google Scholar
• 13. Cohen AA, van Doremalen N, Greaney AJ et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377(6606), eabq0839 (2022).•• Describes the potential of mosaic receptor binding domain action in various animal models.
  Medline CASGoogle Scholar
• 14. Walls AC, Miranda MC, Schäfer A et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 184(21), 5432–5447.e16 (2021).
  Medline CASGoogle Scholar
• 15. Kang Y-F, Sun C, Sun J et al. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. Nat. Commun. 13(1), 2674 (2022).
  Medline CASGoogle Scholar
• 16. Zhang J, Han ZB, Liang Y et al. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. eLife 11, e78633 (2022).
  Medline CASGoogle Scholar
• 17. Olivera-Ugarte S-M, Bolduc M, Laliberté-Gagné M-È et al. A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection. Nanomed. Nanotechnol. Biol. Med. 44, 102584 (2022).
  CASGoogle Scholar
• 18. Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23(3), 189–199 (2023). • Describes the potential of neutralizing antibodies against variants of SARS-CoV-2.
  Medline CASGoogle Scholar
• 19. Martinez DR, Schäfer A, Leist SR et al. Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice. Science 373(6558), 991–998 (2021).
  Medline CASGoogle Scholar
• 20. Volpatti LR, Wallace RP, Cao S et al. Polymersomes decorated with the SARS-CoV-2 spike protein receptor-binding domain elicit robust humoral and cellular immunity. ACS Cent. Sci. 7(8), 1368–1380 (2021).
  Medline CASGoogle Scholar
• 21. Malik JA, Ahmed S, Mir A et al. The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges. J. Infect. Public Health. 15(2), 228–240 (2022).
  MedlineGoogle Scholar